Produodopa (foslevodopa/foscarbidopa; also known as ABBV-951), a continuous infusion formulation of levodopa/carbidopa, will be available to advanced Parkinson’s disease patients in Scotland whose severe motor fluctuations and involuntary movements are no longer controlled by those standard therapies. The Scottish Medicines Consortium (SMC) restricted use of AbbVie’s subcutaneous…
Allyx Therapeutics will advance into Phase 2 clinical development of ALX-001, its investigational therapy for neurodegenerative conditions, in people with Parkinson’s disease. The company announced the move alongside the presentation of positive data from a Phase 1b study (NCT05804383) at the International Conference on Alzheimer’s and…
Athira Pharma’s fosgonimeton (ATH-1017) shows promise as a therapy for neurodegenerative conditions including Parkinson’s disease, according to data presented at the recent International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2024), in Portugal. The investigational small molecule demonstrated “encouraging pro-cognitive effects” in the exploratory…
An experimental therapy called ASHA-091, which was seen to restore normal mitochondria function and possibly be disease modifying in a mouse model of Parkinson’s disease, may soon be moving into clinical trials, its developer, Asha Therapeutics, reports. Problems with the workings of mitochondria, a cell’s…
Risvodetinib, an oral therapy being developed by Inhibikase Therapeutics for Parkinson’s disease, appears to stabilize disease status and severity, according to data covering 25 patients who finished 12 weeks of dosing in an ongoing Phase 2 clinical trial. Over those trial weeks, clinician and patient impressions of disease…
Use of bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell-based therapy, was found to be safe and well tolerated among people with Parkinson’s disease 1.5 years after treatment in a Phase 1 clinical trial. Moreover, the data also showed both that cells survived in the brain even after patients stopped…
bit.bio and The Michael J. Fox Foundation (MJFF) are teaming up in a multiyear effort to develop a range of human cell products for research and drug discovery in Parkinson’s disease. Under the new collaboration agreement, the MJFF will fund specific research on a project-by-project basis, with bit.bio…
Allyx Therapeutics said it will begin a clinical trial by the end of the month to test its lead candidate ALX-001, a disease-modifying therapy for neurodegenerative conditions, in people with Parkinson’s disease. The trial will test the treatment’s safety when administered for 28 days. The U.S. Food and…
A newly launched online tool called TrialPioneer, which makes use of artificial intelligence (AI), aims to help pharmaceutical and biotech companies explore different clinical trial designs for their work in seven major medical conditions, including Parkinson’s disease. Unlearn, a California-based company, developed the new technology to help…
Adding NE3107 to standard carbidopa/levodopa (CD/LD) therapy eases motor and non-motor symptoms in people with Parkinson’s disease, according to data from a Phase 2a trial. “These data suggest that NE3107 as an adjunct therapy to levodopa may hold promise in ameliorating specific non-motor symptoms of Parkinson’s Disease, particularly in sleep/fatigue…
Get regular updates to your inbox.